Familial pulmonary arterial hypertension (fPAH) is associated with mutations in BMPR2.
Introduction
Idiopathic Pulmonary arterial hypertension (PAH) is a disease characterized by increased pressure in the pulmonary circulation, the primary cause of which is not apparent. While it is likely that the disease progresses over several years, in human patients, presentation usually occurs at a relatively late stage, leaving the initial events in the development of the disease obscure. PAH is associated with structural changes in the pulmonary vasculature, including hypertrophy and proliferation of both smooth muscle and endothelium, respectively, resulting in obliteration of small vessels (4) . In addition, PAH is associated with perivascular inflammation (14) .
The familial form is usually associated with mutations in the type 2 receptor for the bone morphogenic protein pathway, BMPR2(17). In order to determine the phenotype and in vivo molecular effect of BMPR2 mutation, we previously created a doxycyclineinducible transgenic mouse, which expressed an intracellular domain truncation of BMPR2, BMPR2 delx4+ , in smooth muscle upon induction. These animals had increased right ventricular systolic pressures (RVSP) (36) , increased cytokines (12, 33) , loss of smooth muscle differentiation (33) , and defects in vasoreactivity and vasoreactivity pathways (33, 42) . However, pulmonary structural changes in this model were limited (36) .
The mutation used in this original BMPR2 delx4+ mouse was derived from family UK21, and consisted of a "T" base insertion at base 504, resulting in a premature stop 18 amino acids into the kinase domain(21). This resulted in loss of the entire intracellular domain and associated functions. The intracellular domain consists of a kinase domain at aa200-500 responsible for phosphorylation of the type I BMP receptor leading to activation of SMAD transcription factors (5) , and a long c-terminal tail from aa500-1038. The kinase domain may also interact with other targets, including Rack1 (44) . The BMPR2 tail has several poorly understood functions, including regulation of p38 and p42/44 MAPK(27, 40) and interaction with LIMK(10), c-Src (37) , and TCTEX(22). Some patient mutations are within this cytoplasmic tail, and leave SMAD functions intact, while causing disruptions to tail functions(21, 26). For example, an arginine to termination mutation at amino acid 899 (R899X) is found in family US33(17).
We hypothesized that this mutation would result in a subset of the manifestations associated with the BMPR2 delx4+ mutation, since SMAD activity remains intact with the R899X mutation. In order to test this hypothesis, we created transgenic mice which express the BMPR2 R899X mutation (BMPR2
R899X
) in smooth muscle when induced by doxycycline. After 9 weeks of induction in adult mice, mice were hemodynamically phenotyped, fluorescent microangiography used to assess vascular pruning, and tissue sections examined by immunohistochemistry. We found that expression of the BMPR2 R899X mutation resulted in increased RVSP accompanied by substantial pulmonary vascular pruning and remodeling. Gene arrays were performed on transgenic mice with both high and low RVSP; we found that stress response, muscle organization and function, proliferation and apoptosis, and developmental pathways were all changed before RVSP increased. After elevation of RVSP there were additional changes in these pathways, as well as increased muscle structural genes and increased angiogenesisrelated genes.
Methods

Construction of Transgenic Mice
TetO 7 -BMPR2 R899X mice were generated at the University of Cincinnati Transgenic
Mouse Core from plasmids we provided. A septad of the tetracycline response element and minimal CMV promoter were used to drive expression of murine BMPR2 with an argenine to stop mutation at amino acid 899, with c-terminal FLAG tag, referred to as
, followed by the beta-globin intron and polyadenylation sequence.
Complete sequence of the transgene has been deposited in Genbank as EU919427.
Heterozygotes in TetO 7 -BMPR2 R899X were crossed to homozygotes in our previously published(36) SM22-rtTA transgenic mouse with smooth muscle specific expression of the reverse tetracycline transactivator. This resulted in mice that were universally heterozygous for the SM22-rtTA, and approximately half of which were heterozygous for TetO 7 -BMPR2
R899X
. We thus used transactivator-only littermate controls. Starting at 4
week of age, all mice were fed doxycycline in chow (1g/kg) for 9 weeks when phenotyping was performed. All animal studies were preapproved by the UCHSC Institutional Animal Care and Use Committee (IACUC).
Heart Catheterization and Fluorescent Microangiography
Mice are given Tribromoethanol (500 mg/kg IP) to induce a surgical plane of anesthesia. Once blood pressure and volume data is collected, the caudal suture is re-loosened and the catheter removed. 100U of heparin is then injected through the jugular incision to prevent clotting. The suture is the re-tightened to prevent bleeding. The animals are then removed from the surgical table to a dissecting area.
Plane of anesthesia is re-determined post-surgery and an overdose of sodium pentobarbital is administered if the withdrawal reflex is returning. After complete loss of withdrawal reflex, an incision is made just below the xiphoid process and the ventral portion of the rib cage is cut away being careful not to nick the lungs. A small cut is then Sections for fluorescent microangiography are cut using a vibratome. 
Luciferase-Reporter Assay
Western Blot and Immunohistochemistry
Western blots were performed as previously described (12) , using primary antibodies at 1:200 dilution and secondary antibodies at 1:3000 dilution. Primary antibodies included Id1 (Santa Cruz SC-488), phospho-Smad1 (Cell Signaling #9511), and phospho-p38
(Santa Cruz SC-7973).
Immunohistochemistry was performed as previously described (33) , using the following 
Affymetrix Arrays
Total RNA was isolated using an RNeasy mini kit (Qiagen, Valencia CA) from 30mg of right lung from six individual mice. Samples were prepared for Affymetrix arrays using 
Array Analysis
Affymetrix Cel files were loaded into dChip 2007 array analysis software. The dChip algorithm is capable of detecting significant differences at signal strengths lower than those usable in Microarray Suite(19) (Affymetrix, Santa Clara, CA). Overall signal strength from arrays was normalized to the median array, and expression levels determined using the perfect match/mismatch (PM/MM) algorithm. Gene ontology was determined using the Classify Genes tool within dChip (45) , with gene ontology files downloaded from the Gene Ontology Consortium (www.geneontology.org)(1). Our definition for changed genes was a 1.2x change for each of four pairwise comparisons with a minimum absolute change of 100, which results in a false discovery rate of 27%
Results
BMPR2
R899X expression is correctly localized, and results in increased p38 MAPK and p42/44 phosphorylation but unchanged SMAD activity.
In order to verify that the transgene was expressed in the correct tissue type and was correctly trafficked to the cell surface, adult SM22-rtTA x TetO 7 -BMPR2 R899X mice were fed doxycycline at 1g/kg in chow for three days, then sacrificed and immunohistochemistry for the FLAG tag performed. We found that the FLAG tag is correctly localized to the cell surface by confocal microscopy ( Figure 1A ) and colocalizes with alpha smooth muscle actin in both pulmonary artery and airway smooth muscle ( Figure 1B ). Columnar epithelial cells and elastic lamina are false positive, as
shown by secondary antibody-only control (supplemental figure 1A ). Supplemental figure 1B shows serial sections double stained with either FLAG tag and actin or vWf (endothelial marker) and actin, showing that non-muscularized vessels do not express FLAG tag, further supporting smooth muscle specificity. While we can not rule out expression below the threshold of detection in other tissue types, these data indicate that the transgene is substantially made in the correct cell type, and is correctly expressed on the cell surface.
While much of downstream signaling from the BMPR2 R899X mutation has previously been published(27), we wished to confirm the reported effects. We cotransfected vascular smooth muscle cells in culture with either wild type or R899X mutant BMPR2 and the pBRE luciferase reporter construct for Smad activity(23). We found that there was no difference between wild-type and mutant receptor in either baseline activity or activity with 5, 15, or 50 ng/ml BMP4 added ( Figure 2A ). We obtained similar results in Cos7 epithelial cells, suggesting that the effect of this mutation on Smad signaling is not cell type specific (supplemental figure 2A) . In whole animals we saw a slight, but not statistically significant, increase in Smad1 phosphorylation ( Figure 2B ). Id1 protein expression, a target of SMAD signaling, was not changed in the same animals, however ( Figure 2C ), nor was expression of Id1,2, or 3 (Supplemental Figure 2B) . Based on these data we conclude that the R899X mutation does not have a significant effect on Smad activity in cell culture, and in vivo may result in slightly increased, rather than decreased, Smad phosphorylation, likely via feedback not present in cell culture.
We also examined other downstream BMPR2 targets including p38, p42/44, and LIMK.
We found a consistent increase in p38 phosphorylation ( Figure 2D ), by densitometry almost 3x normalized to total p38 and about 1.5x normalized to β-actin. We also found an increase in p42/44 phosphorylation by IHC(Supplemental Figure 2C) , apparently in both endothelium and smooth muscle, implying a paracrine effect. Contrary to expectation, we did not see alteration in phosphorylation of cofilin, a LIMK target (Supplemental Figure 2D ) in whole lung homogenates. We cannot rule out a tissuespecific effect obscured by use of whole lung, as array data below suggests alterations in actin organization pathways. showed an almost perfect correlation with RVSP ( Figure 3B ). Thus, there was strong support in both heart and pulmonary vessel muscularization for the pressures measured. This means that in some lesions, the cells filling the vessels do not express transgene ( Figure 5C ), demonstrating that in this case the effect of the mutation is necessarily through paracrine signaling. In fact, some non-muscularized vessels also appear to be filled with endothelial cells (supplemental figure 3a) and increased proliferating cells (by PCNA staining) do not appear to be limited to muscularized vessels (supplemental figure   3b) , suggesting that the mutation in this context may lead to a paracrine proliferative effect. These sorts of structural changes are never seen in hypoxic mice, indicating that they are unlikely to be the result of increased pressure alone.
The transgene is expressed in all smooth muscle in the body (supplemental figure 3c shows expression in smooth muscle in kidney), however other organs do not appear to have the gross abnormalities seen in lungs (supplemental figure 3d shows liver and kidney Vessels which were filled primarily with CD133 positive cells were also CD45 positive ( Figure 6D ); from our current study design we cannot determine whether this is an earlier stage in the development of lesions such as those in figure 6C , or a different type of lesion. In lungs from control mice, only a few isolated alveolar macrophages can be found, and both T-cells and CD133 staining were essentially never found. Comparison of controls to BMPR2 R899X mice with normal RVSP allows examination of pathways dysregulated by mutation and compensation for the mutation, without the complicating factor of additional changes caused by elevated pulmonary pressure. In this comparison, we found 181 unique named genes with altered expression using criteria with a false discovery rate of 27% -our goal was sensitivity over specificity. When sorted into gene ontology groups, we found that the majority fell into four broad categories;
weeks of BMPR2
developmental genes, stress response, muscle structure & function, and cell cycle ( Figure   8A , Supplemental Table 1 ).
Examples of these genes are shown in Figure 8B . These include the developmental gene this data whether the change in each of these specific genes is part of pathogenesis, or compensatory. In either case, however, the ontology group to which they belong is implicated in the early etiology of BMPR2-mediated PAH.
Statistically overrepresented gene ontology groups are likely to have a lower number of falsely discovered genes. For instance, about 4% of genes on the array are involved with actin dynamics; with 181 genes altered, one would expect about (.04 x 181=) seven to be actin dynamics-related if they were randomly distributed, with two of these spurious.
Since we actually have 22 genes in this category, the category is highly overrepresented and thus likely to be a real change; in addition, we still only expect two of the genes in this category to be falsely discovered.
Comparing genes dysregulated in the BMPR2 R899X model to those we have previously reported in our SM22-rtTA x TetO7-BMPR2 delx4+ model, we found both substantial overlap as well as major differences, which allows us to make guesses as to domain function ( Figure 8B ). The most striking differences are genes dysregulated in The BMPR2 R899X mice with elevated RVSP had substantial additional changes to gene expression; using the same criteria as above, an additional 269 changed (Supplemental Table 2 ). These include many genes which are clearly suggestive of response to injury. In figure 9A , these include Heme oxygenase 1 (Hmox1), an oxidative stress response(28), CD44, a cell adhesion marker characteristic of response to endothelial barrier injury (31) , and myotrophin (Mtpn), a pressure and stretch sensor that triggers hypertrophy (30) .
Angiogenesis factors also increase with elevated RVSP (Figure 9B ), including canonical angiogenesis genes VegfA and Angiopoietin 1, but also platelet derived growth factor receptor alpha (PdgfRA), required for fibroblast recruitment in angiogenesis (7). Finally, the advent of high right ventricular pressure results in increases in vasoreactivity-related genes ( Figure 9C) show substantial altered expression until after RVSP increases (Figure 9 ), suggesting that they are a response to increased pulmonary vascular pressure, not the cause of it.
Integrating the data from this study with our past studies (33, 36) and recent data from the literature(15, 32), we hypothesize that a decrease in BMP signal results in activation of injury repair mechanisms, with each downstream BMPR2 effector pathway, SMAD, MAPK, and actin organization, playing a different role. Decreased SMAD signaling through BMPR2 results in both a switch in smooth muscle from a contractile to a synthetic state and increased cytokine expression (12, 33) . Increased p38 MAPK phosphorylation ( Figure 2D ) drives downstream stress responses, possibly including proliferation(39) ( Figure 8A ,B, Supplemental Table 1 ). Direct BMPR2-mediated alterations in actin organization through LIMK1 and TCTEX may result in multiple effects seen in PAH in patients, including muscle migration (18) , matrix deposition(3), and inflammatory cell adhesion (8, 29) . Different BMPR2 mutations may cause dysfunction in any or all of these elements, but one can easily imagine how overactive injury response through any of these pathways would predispose to PAH.
These studies were done at a single time-point, and so cause and effect relationships between these elements are essentially a matter for speculation. However, the differences between those animals that had normal RVSP and those that had high RVSP leads us to the following hypothesis for pathogenesis.
Loss of proper tail domain function leads to alterations in actin organization pathways through LIMK and TCTEX. These either directly lead to recruitment of circulating cells through alteration in adhesion factors, or they lead to pulmonary vascular stiffening or constriction. In the latter case, this is insufficient to directly increase RVSP, but since shear stress is exquisitely sensitive to vessel diameter(25), even subtle changes in vessel diameter can radically alter shear stress and thus endothelial injury. Some combination of direct effects of BMPR2 mutation, signaling from the circulating cells, and direct endothelial injury result in increased proliferation. This proliferation results in blocked small vessels in the pulmonary vasculature ( Figure 7 ). When pruning is sufficiently advanced, RVSP starts to increase, leading to conventional muscularization of all pulmonary vessels. The combination of increased pressure and either the Bmpr2 mutation or the presence of inflammatory cells( Figure 6 ) leads to the larger lesions; while these happen in secondary forms of human PAH, they are never seen purely as the result of increased pressure in mice. The fact that some of the concentric muscular lesions are CD133 positive suggests that they are least partially populated by recruitment of circulating progenitors
At the start of this study, our goal was to find out which subset of the phenotype found in the earlier SM22-rtTA x TetO 7 -BMPR2 delx4+ mouse model was due to loss of the tail domain and, by deduction, the loss of the kinase domain. The earlier model had increased RVSP likely due to defects in vasoreactivity and loss of complete smooth muscle differentiation (33, 36, 42) . While it also had defects in cytokine signaling (12, 33) , these had no obvious impact on phenotype. The BMPR2 delx4+ mouse looked like it was best considered a model of asymptomatic mutation carriers, who may have some baseline defects in vasoreactivity(11), but are in need of a second hit to develop disease.
The much more penetrant phenotype seen in the SM22-rtTA x TetO 7 -BMPR2 R899X mice, which at least nominally have a less severe mutation, was thus somewhat surprising.
There are two potential explanations for this. First, it may just be a dose effect; the by which BMPR2 mutation can directly lead to pulmonary arterial hypertension, rather than the only mechanism.
In summary, this is the first report of an animal model demonstrating extensive pulmonary vascular structural changes resulting from Bmpr2 mutation in vivo. The power of this model is that it will now be possible to dissect the molecular etiology of the disease in detail, with correlation of small molecule inhibitors to alleviation of specific subsets of the molecular, hemodynamic and histologic phenotype. This model should be extremely useful to the research community both in examining early molecular and physical events in the development of PAH, and as a platform to validate potential treatments. The cells filling the lumen in some lesions do not express R899X transgene (blue nuclei seen in combined panel do not also express FLAG tag). Figure 6C ).
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